WHO第5版与ICC 2022髓系肿瘤分类比较综述
该综述比较了2022年近乎同时发布的WHO第5版造血淋巴肿瘤分类(WHO-HAEM5)与国际共识分类(ICC)在髓系肿瘤分类上的差异。两系统均强调整合形态学、细胞遗传学和分子遗传学,但在AML原始细胞阈值、MDS-AML界面定义及TP53突变疾病分类等方面存在分歧,并影响预后分层、治疗决策和临床试验资格。近期比较队列研究显示MDS伴原始细胞增多、AML伴骨髓增生异常相关特征及TP53突变肿瘤存在显著重分类率,预后主要由分子特征而非原始细胞百分比驱动。
要点
- WHO-HAEM5与ICC 2022在AML原始细胞阈值、MDS-AML界面及TP53突变疾病分类上存在临床意义分歧。
- 分类差异影响预后分层、治疗决策及临床试验资格。
- MDS伴原始细胞增多、AML伴骨髓增生异常相关特征及TP53突变肿瘤重分类率较高。
核心结论
- WHO-HAEM5与ICC 2022在髓系肿瘤分类上存在多个临床意义分歧,影响预后分层、治疗决策和临床试验资格。
- 近期比较队列研究显示MDS伴原始细胞增多、AML伴骨髓增生异常相关特征及TP53突变肿瘤存在显著重分类率。
- 预后主要由 underlying molecular features 而非单纯原始细胞百分比驱动。
研究设计与样本
- 比较综述,系统比较WHO-HAEM5与ICC 2022髓系肿瘤分类并汇总新兴真实世界结局数据。
主要发现
- 两系统在AML原始细胞阈值、MDS-AML界面定义及TP53突变疾病分类方面存在分歧。
- 比较队列研究显示MDS伴原始细胞增多、AML伴骨髓增生异常相关特征及TP53突变肿瘤存在显著重分类率。
- 预后主要由分子特征而非原始细胞百分比驱动。
关键数值与推荐
- AML原始细胞阈值:WHO-HAEM5与ICC 2022存在分歧。
- MDS-AML界面定义:两系统存在分歧。
- TP53突变疾病分类:两系统存在分歧。
- MDS伴原始细胞增多、AML伴骨髓增生异常相关特征及TP53突变肿瘤重分类率较高。
临床怎么用
- 病理科医生应了解两系统在AML原始细胞阈值、MDS-AML界面及TP53突变分类上的差异。
- 诊断报告需注意分类选择对预后分层、治疗决策及临床试验资格的影响。
- 应结合分子遗传学特征综合评估髓系肿瘤,而非仅依赖原始细胞百分比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The near-simultaneous publication of the World Health Organization (WHO) 5th Edition classification of hematolymphoid tumors (WHO-HAEM5) and the International Consensus Classification (ICC) in 2022 represents a pivotal moment in the taxonomy of myeloid neoplasms. Both systems emphasize integration of morphology, cytogenetics, and molecular genetics, yet they diverge in several clinically meaningful areas, including blast thresholds for acute myeloid leukemia (AML), definition of the myelodysplastic syndrome (MDS)-AML interface, and categorization of TP53-mutated disease [TP53mut MN] [1-3]. These differences extend beyond nomenclature, influencing prognostic stratification, therapeutic decision-making, and eligibility for clinical trials [4-7]. Recent comparative cohort studies demonstrate substantial reclassification rates, particularly among MDS with excess blasts, AML with myelodysplasia-related features, and TP53-mutated neoplasms, with prognosis driven largely by underlying molecular features rather than blast percentage alone [8-11]. This review provides a comprehensive comparison of WHO-HAEM5 and ICC 2022, synthesizes emerging real-world outcome data, and discusses implications for diagnostic practice, harmonization efforts, and future refinement of myeloid neoplasm classification [12-14].
引用
- Koorse Germans S, Weinberg OK. Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms. Hum Pathol. 2026. PMID: 41720165. doi:10.1016/j.humpath.2026.106077
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。